The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

An in-line performance of orforglipron could ... The analyst firm also compared the weight loss outcomes of Novo Nordisk's products with those of orforglipron, noting the latter's compelling ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Apple stock rises after falling Thursday by 4%, the most since August, Qorvo stock jumps following a report that activist ...

In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...